Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis

BACKGROUND: Thrombin activatable fibrinolysis inhibitor (TAFI) is a plasma zymogen, which can be converted to activated TAFI (TAFIa) through proteolytic cleavage by thrombin, plasmin, and most effectively thrombin in complex with the endothelial cofactor thrombomodulin (TM). TAFIa is a carboxypeptid...

Descripción completa

Detalles Bibliográficos
Autores principales: Bazzi, Zainab A., Lanoue, Danielle, El-Youssef, Mouhanned, Romagnuolo, Rocco, Tubman, Janice, Cavallo-Medved, Dora, Porter, Lisa A., Boffa, Michael B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879731/
https://www.ncbi.nlm.nih.gov/pubmed/27221823
http://dx.doi.org/10.1186/s12885-016-2359-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879731/
https://www.ncbi.nlm.nih.gov/pubmed/27221823
http://dx.doi.org/10.1186/s12885-016-2359-1

Ejemplares similares